Tags

Type your tag names separated by a space and hit enter

Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma.
J Dermatolog Treat 2019; :1-6JD

Abstract

BACKGROUND

Infantile hemangioma (IH) in most cases can be a self-limited condition; however, it may be ulcerated, infected, causing organ function disability and even death. Vascular endothelial growth factor (VEGF) has a role in IH. Bevacizumab is a monoclonal antibody against VEGF-A.

OBJECTIVES

We aimed to evaluate and compare the efficacy of intralesional injection of bevacizumab versus triamcinolone acetonide (TAC) in IH.

METHODS

Thirty patients with IH were included in this study, divided into two equal groups, and treated with intralesional injection; the first group by bevacizumab and the second group by TAC. The injections in both groups were given every 4 weeks for six sessions. Assessment of the clinical response was done by the hemangioma activity score (HAS) and visual analog scale (VAS).

RESULTS

Both treatment modalities gave similar initial improvement after three sessions. However, with continuing injection sessions, bevacizumab reached a response's plateau and TAC gave better significant results after six injection sessions reading both HAS (p = .0017) and VAS (p ≤.001).

CONCLUSION

Both intralesional injection of bevacizumab and TAC were safe and effective treatments in early proliferative IH after three sessions, however, TAC injection was significantly better than bevacizumab after six sessions.

Authors+Show Affiliations

a Department of Dermatology, Venereology and Andrology, Faculty of Medicine , Benha University , Benha , Egypt.a Department of Dermatology, Venereology and Andrology, Faculty of Medicine , Benha University , Benha , Egypt.a Department of Dermatology, Venereology and Andrology, Faculty of Medicine , Benha University , Benha , Egypt.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30835573

Citation

Sabry, Hanan H., et al. "Intralesional Injection of Bevacizumab Versus Triamcinolone Acetonide in Infantile Hemangioma." The Journal of Dermatological Treatment, 2019, pp. 1-6.
Sabry HH, Sorour NE, Akl EM. Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. J Dermatolog Treat. 2019.
Sabry, H. H., Sorour, N. E., & Akl, E. M. (2019). Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. The Journal of Dermatological Treatment, pp. 1-6. doi:10.1080/09546634.2019.1590521.
Sabry HH, Sorour NE, Akl EM. Intralesional Injection of Bevacizumab Versus Triamcinolone Acetonide in Infantile Hemangioma. J Dermatolog Treat. 2019 Mar 5;1-6. PubMed PMID: 30835573.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. AU - Sabry,Hanan H, AU - Sorour,Neveen E, AU - Akl,Essam M, Y1 - 2019/03/05/ PY - 2019/3/6/pubmed PY - 2019/3/6/medline PY - 2019/3/6/entrez KW - Infantile hemangioma KW - bevacizumab KW - triamcinolone acetonide SP - 1 EP - 6 JF - The Journal of dermatological treatment JO - J Dermatolog Treat N2 - BACKGROUND: Infantile hemangioma (IH) in most cases can be a self-limited condition; however, it may be ulcerated, infected, causing organ function disability and even death. Vascular endothelial growth factor (VEGF) has a role in IH. Bevacizumab is a monoclonal antibody against VEGF-A. OBJECTIVES: We aimed to evaluate and compare the efficacy of intralesional injection of bevacizumab versus triamcinolone acetonide (TAC) in IH. METHODS: Thirty patients with IH were included in this study, divided into two equal groups, and treated with intralesional injection; the first group by bevacizumab and the second group by TAC. The injections in both groups were given every 4 weeks for six sessions. Assessment of the clinical response was done by the hemangioma activity score (HAS) and visual analog scale (VAS). RESULTS: Both treatment modalities gave similar initial improvement after three sessions. However, with continuing injection sessions, bevacizumab reached a response's plateau and TAC gave better significant results after six injection sessions reading both HAS (p = .0017) and VAS (p ≤.001). CONCLUSION: Both intralesional injection of bevacizumab and TAC were safe and effective treatments in early proliferative IH after three sessions, however, TAC injection was significantly better than bevacizumab after six sessions. SN - 1471-1753 UR - https://www.unboundmedicine.com/medline/citation/30835573/Intralesional_injection_of_bevacizumab_versus_triamcinolone_acetonide_in_infantile_hemangioma_ L2 - http://www.tandfonline.com/doi/full/10.1080/09546634.2019.1590521 DB - PRIME DP - Unbound Medicine ER -